rucaparib (Rubraca): FDA status

Approved Approved Dec 17, 2025. Indication: BRCA mutated metastatic castration resistant prostate cancer. Company: pharmaand GmbH.

Regulatory history

All products in the FDA Tracker

Loading today's edition…